Karabacakoğlu, AydınAdıgüzel, YükselKaraköse, SerdarKayaçetin, ErtuğrulHaykır, Rahime2020-03-262020-03-2620061300-4948https://hdl.handle.net/20.500.12395/20849Background/aims: We evaluated the characterization and detection of liver lesions using mangafodipir trisodiutn. Methods: A total of 51 patients with liver lesions [13 hepatocellular carcinomas , 18 metastases, 14 hemangiomas, three cholangiocellular carcinomas, two hydatic cysts, and one focal nodular hyperplasia (FNH)] were examined by unenhanced and mangafodipir trisodium -enhanced MRI. Results: After administration of mangafodipir trisodium by slow intravenous infusion, mangafodipir trisodium -enhanced MRI was performed at 15-30 min and 24 h. The enhancement appeared in normal liver parenchyma and all of the hepatocellular lesions (HCCs and FNH). The lesions in hepatocellular carcinomas patients showed a non-homogeneous enhancement pattern. Non-hepatocellular lesions (hemangiomas, metastases, CCCs) had no enhancement on mangafodipir trisodium -enhanced MRI examinations. The rim-like enhancement pattern was demonstrated in all patients with cholangiocellular carcinomas, and in 14 metastases and 11 hemangiomas. Conclusions: Mangafodipir trisodium -enhanced MRI permits reliable distinction between hepatocellular and non-hepatocellular tumors. Mangafodipir trisodium -enhanced MRI can show more functional and morphologic features of hepatocellular lesions. Some non-hepatocellular lesions which went undetected on unenhanced MRI were visualized after contrast enhancement of the liver. The rim-like enhancement pattern is not specific for metastases. Mangafodipir trisodium -enhanced MRI is safe and well tolerated and may aid in noninvasive diagnosis of liver lesions.eninfo:eu-repo/semantics/closedAccessLiverMangafodipir trisodiumMRIArticle17316417116941248Q3